Helmerich & Payne Inc. Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.25 (market cap $3.91B), while Roivant Sciences Ltd. Common Shares trades at $33.68 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 6.4× Helmerich & Payne Inc. Common Stock's market cap, and Helmerich & Payne Inc. Common Stock pays a 2.56% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| HP | ROIV | |
|---|---|---|
Market Cap | $3.91B | $24.99B |
Volume | 800,382 | 4,711,562 |
Sector | Energy | Health |
52-Week High | $47.64 | $41.81 |
52-Week Low | $23.11 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $5.54B | $21.25B |
Dividend Yield | 2.56% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.
Read more on HP →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →